Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XB002 dose-escalation and expansion study in advanced solid tumors
NL-OMON56126Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of XB002 in Nonhematologic neoplasms (3 arms), sponsored by Exelixis, Inc. Primary endpoint: Objective response rate. Started Dec 2023; status: recruiting.
02
Drugs
XB002
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON56126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56126.